Antibodies to insulin-like growth factor I receptor

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S133100, C424S130100, C530S387100, C530S387300, C530S388220, C530S388850

Reexamination Certificate

active

07037498

ABSTRACT:
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4740461 (1988-04-01), Kaufman
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 4968615 (1990-11-01), Koszinowski et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5179017 (1993-01-01), Axel et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5625825 (1997-04-01), Rostoker et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693792 (1997-12-01), Torii et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5750172 (1998-05-01), Meade et al.
patent: 5756687 (1998-05-01), Denman et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5777085 (1998-07-01), Co et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5886152 (1999-03-01), Nakatani et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5985615 (1999-11-01), Jakobovits et al.
patent: 5994619 (1999-11-01), Stice et al.
patent: 5998209 (1999-12-01), Jokobovits et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6091001 (2000-07-01), Jakobovits et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6130364 (2000-10-01), Jakobovits et al.
patent: 6146629 (2000-11-01), Dagan et al.
patent: 6657103 (2003-12-01), Kucherlapati et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 0 216 846 (1987-04-01), None
patent: 0 256 055 (1988-02-01), None
patent: 0 323 997 (1989-07-01), None
patent: 0 338 841 (1989-10-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 818 442 (1998-01-01), None
patent: 0 931 788 (1999-07-01), None
patent: 1 004 578 (2000-05-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/02190 (1992-02-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 93/01288 (1993-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/14451 (1998-04-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 99/07675 (1999-02-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 99/45031 (1999-09-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 99/53049 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 99/62890 (1999-12-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 00/50067 (2000-08-01), None
patent: WO 00/56772 (2000-09-01), None
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Groves et al (Hybridoma 6:71, 1987.
Rubini et al Experimental Cell Research 251:22-32, 1999.
Colman, Research in immunology 145:33-36, 1994.
DiGiovanni, John, et al., “Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice,”Proc. Natl. Acad. Sci. USA,97:3455-3460 (2000).
Drexhage, H.A. & Wulffraat, N.M., “Endocrine autoimmune diseases,”Netherlands Journal of Medicine,45:285-293 (1994).
Kim, Bhumsoo, et al., “Insulin receptor substrate 2 and shc play different roles in insulin-like growth factor I signaling,”Journal of Biological Chemistry,274:34543-34550 (1998).
Smith, Lois E., et al., “Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor,”Nature Medicine,5:1390-1395 (1999).
Tappy, Luc, et al., “Antibodies to insulin-like growth factor I receptors in diabetes and other disorders,”Diabetes,37:1708-1714 (1988).
Thompson, Kathleen, et al., “Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature,”Pediatric Research,32:455-459 (1992).
Weightman, David R., et al., “Autoantibodies to IGF-1 binding sites in thyroid associated opthalmopathy,”Autoimmunity,16:251-257 (1993).
Wraight, Christopher, et al., “Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides,”Nature Biotechnology,18 :521-526 (2000).
Li, S.-L. et al., “Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth,”Cancer Immunology and Immunotherapy,49:243-252 (2000).
Hermanto, U. et al., “Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Prol

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies to insulin-like growth factor I receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to insulin-like growth factor I receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to insulin-like growth factor I receptor will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3526340

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.